Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neurofibrosarcoma 1Melanoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Carcinoma, Basal Cell 1

Interventions

Doxorubicin 6Specimen Handling 5Radiotherapy 3Radiation 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Biopsy 3pembrolizumab 2liposomal doxorubicin 2eribulin 2Ifosfamide 2toripalimab 1talimogene laherparepvec 1rucaparib 1ribociclib 1regorafenib 1peposertib 1pazopanib 1olaratumab 1olaparib 1lenvatinib 1futibatinib 1durvalumab 1dinutuximab 1cemiplimab 1cediranib 1cabozantinib 1avelumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyosarcoma × BO-112 × 1 year × Clear all
NCT04420975 2026-03-10

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
14 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡